Alantolactone induces activation of apoptosis in human hepatoma cells

Food and Chemical Toxicology

Volumn 50, Issue 9, 2012, Pages 3313-3319

  Lei, Jia Chuan ^a,b   Yu, Jian Qing ^b   Yin, Yan ^b   Liu, Yan Wen ^c   Zou, Guo Lin ^b  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b WUHAN UNIVERSITY   (China)

^c HUBEI UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Alantolactone; Apoptosis; Cell cycle; Liver cancer; NF B

Indexed keywords

ALANTOLACTONE; CASPASE 3; CASPASE 8; CASPASE 9; CYTOCHROME C; DEATH RECEPTOR; DNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BID; PROTEIN P53; TRANSCRIPTION FACTOR RELA;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL STRAIN BEL 7402; CELL STRAIN HEPG2; CELL STRAIN SMMC 7721; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME RELEASE; G2 PHASE CELL CYCLE CHECKPOINT; GROWTH INHIBITION; HEPATOMA CELL; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL RESPIRATION; MOLECULAR INTERACTION; PROTEIN FAMILY; SIGNAL TRANSDUCTION;

APOPTOSIS; BH3 INTERACTING DOMAIN DEATH AGONIST PROTEIN; CARCINOMA, HEPATOCELLULAR; CASPASE 8; CYTOCHROMES C; DOSE-RESPONSE RELATIONSHIP, DRUG; HEP G2 CELLS; HUMANS; LACTONES; LIVER NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES; SESQUITERPENES, EUDESMANE;

EID: 84864144305     PISSN: 02786915     EISSN: 18736351     Source Type: Journal    
DOI: 10.1016/j.fct.2012.06.014     Document Type: Article

References (49)

1. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat. Rev. Cancer 2002, 2:420-430.
2. Bruix J., Boix L., Sala M., Llovet J.M. Focus on hepatocellular carcinoma. Cancer Cell 2004, 5:215-219.
3. Bucher N., Britten C.D. G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer. Br. J. Cancer 2008, 98:523-528.
4. Budihardjo I., Oliver H., Lutter M., Luo X., Wang X. Biochemical pathways of caspase activation during apoptosis. Annu. Rev. Cell Dev. Biol. 1999, 15:269-290.
5. Danial N.N., Korsmeyer S.J. Cell death: critical control points. Cell 2004, 116:205-219.
6. El-Serag H.B., Rudolph K.L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132:2557-2576.
7. Evan G.I., Vousden K.H. Proliferation, cell cycle and apoptosis in cancer. Nature 2001, 411:342-348.
8. Farazi P.A., DePinho R.A. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat. Rev. Cancer 2006, 6:674-687.
9. Feitelson M.A. Parallel epigenetic and genetic changes in the pathogenesis of hepatitis virus-associated hepatocellular carcinoma. Cancer Lett. 2006, 239:10-20.
10. Fulda S., Debatin K.M. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006, 25:4798-4811.
11. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
12. Harris C.C. P53 Tumor suppressor gene: from the basic research laboratory to the clinic-an abridged historical perspective. Carcinogenesis 1996, 17:1187-1198.
13. Hartwell L.H., Kastan M.B. Cell cycle control and cancer. Science 1994, 266:1821-1828.
14. Hengartner M.O. The biochemistry of apoptosis. Nature 2000, 407:770-776.
15. Herrmann M. A rapid and simple method for the isolation of apoptotic DNA fragments. Nucleic Acids Res. 1994, 22:5506-5507.
16. Hockenbery D.M., Oltvai Z.N., Yin X.M., Milliman C.L., Korsmeyer S.J. Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell 1993, 75:241-251.
17. Karin M. Nuclear factor-κB in cancer development and progression. Nature 2006, 441:431-436.
18. Karin M., Greten F.R. NF-κB: linking inflammation and immunity to cancer development and progression. Nat. Rev. Immunol 2005, 5:749-759.
19. Khan N., Hadi N., Afaq F., Syed D.N., Kweon M.H., Mukhtar H. Pomegranate fruit extract inhibits prosurvival pathways in human A549 lung carcinoma cells and tumor growth in athymic nude mice. Carcinogenesis 2007, 28:163-173.
20. Kolewe M.E., Gaurav V., Roberts S.C. Pharmaceutically active natural product synthesis and supply via plant cell culture technology. Mol. Pharm. 2008, 5:243-256.
21. Kong R., Sun B., Jiang H., Pan S., Chen H., Wang S., Krissansen G.W., Sun X. Downregulation of nuclear factor-κB p65 subunit by small interfering RNA synergizes with gemcitabine to inhibit the growth of pancreatic cancer. Cancer Lett. 2010, 291:90-98.
22. Konishi T., Shimada Y., Nagao T., Okabe H., Konoshima T. Antiproliferative sesquiterpene lactones from the roots of Inula helenium. Biol. Pharm. Bull 2002, 25:1370-1372.
23. Koybasi S., Senkal C.E., Sundararaj K., Spassieva S., Bielawski J., Osta W., Day T.A., Jiang J.C., Jazwinski S.M., Hannun Y.A., Obeid L.M., Ogretmen B. Defects in cell growth regulation by C18:0-ceramide and longevity assurance gene 1 in human head and neck squamous cell carcinomas. J. Biol. Chem. 2004, 279:44311-44319.
24. Kroemer G., Reed J.C. Mitochondrial control of cell death. Nat. Med. 2000, 6:513-519.
25. Kruse J.P., Gu W. Modes of p53 regulation. Cell 2009, 137:609-622.
26. Kucharczak J., Simmons M.J., Fan Y., Gélinas C. To be, or not to be: NF-kappaB is the answer - role of Rel/NF-kappaB in the regulation of apoptosis. Oncogene 2003, 22:8961-8982.
27. Kutuk O., Letai A. Alteration of the mitochondrial apoptotic pathway is key to acquired paclitaxel resistance and can be reversed by ABT-737. Cancer Res. 2008, 68:7985-7994.
28. Lawrence N.J., McGown A.T., Nduka J., Hadfield J.A., Pritchard R.G. Cytotoxic Michael-type amine adducts of α-methylene lactones alantolactone and isoalantolactone. Bioorg. Med. Chem. Lett. 2001, 11:429-431.
29. Leu J.I.J., Dumont P., Hafey M., Murphy M.E., George D.L. Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex. Nat. Cell Biol. 2004, 6:443-450.
30. Manly S.P., Padmanabha R., Lowe S.E. Natural products or not? How to screen for natural products in the emerging HTS paradigm. Methods Mol. Biol. 2002, 190:153-168.
31. Mazzaferro V., Regalia E., Doci R., Andreola S., Pulvirenti A., Bozzetti F., Montalto F., Ammatuna M., Morabito A., Gennari L. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N. Engl. J. Med. 1996, 334:693-699.
32. McDonald E.R., El-Deiry W.S. Cell cycle control as a basis for cancer drug development. Int. J. Oncol. 2000, 16:871-886.
33. Oda E., Ohki R., Murasawa H., Nemoto J., Shibue T., Yamashita T., Tokino T., Taniguchi T., Tanaka N. Noxa, a BH3-only member of the BcL-2 family and candidate mediator of p53-induced apoptosis. Science 2000, 288:1053-1058.
34. Owa T., Yoshino H., Yoshimatsu K., Nagasu T. Cell cycle regulation in the G1 phase: a promising target for the development of new chemotherapeutic anticancer agents. Curr. Med. Chem 2000, 8:1487-1503.
35. Rimassa L., Santoro A. The present and the future landscape of treatment of advanced hepatocellular carcinoma. Dig. Liver Dis. 2010, 42S:S273-S280.
36. Rocha S., Perkins N.D. ARF the integrator: linking NF-kappaB, p53 and checkpoint kinases. Cell Cycle 2005, 4:756-759.
37. Saklani A., Kutty S.K. Plant-derived compounds in clinical trials. Drug Discov. Today 2008, 13:161-171.
38. Sausville E.A., Johnson J.I. Molecules for the millennium: how will they look? New drug discovery in the year 2000. Br. J. Cancer 2000, 83:1401-1404.
39. Schwartsmann G., Ratain M.J., Cragg G.M., Wong J.E., Saijo N., Parkinson D.R., Fujiwara Y., Pazdur R., Newman D.J., Dagher R., Di Leone L. Anticancer drug discovery and development throughout the world. J. Clin. Oncol. 2002, 20:47S-59S.
40. Van Antwerp D.J., Martin S.J., Kafri T., Green D.R., Verma I.M. Suppression of TNF-a-induced apoptosis by NF-nB. Science 1996, 274:787-789.
41. Vazquez A., Bond E.E., Levine A.J., Bond G.L. The genetics of the p53 pathway, apoptosis and cancer therapy. Nat. Rev. Drug Discov. 2008, 7:979-987.
42. Ventura A., Kirsch D.G., McLaughlin M.E., Tuveson D.A., Grimm J., Lintault L., Newman J., Reczek E.E., Weissleder R., Jacks T. Restoration of p53 function leads to tumour regression in vivo. Nature 2007, 445:661-665.
43. Vermeulen K., Berneman Z.N., Van Bockstaele D.R. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif. 2003, 36:165-175.
44. Wu G.S., Ding Z. Caspase 9 is required for p53-dependent apoptosis and chemosensitivity in a human ovarian cancer cell line. Oncogene 2002, 21:1-8.
45. Xiao D., Pinto J.T., Gundersen G.G., Weinstein I.B. Effects of a series of organosulfur compounds on mitotic arrest and induction of apoptosis in colon cancer cells. Mol. Cancer Ther. 2005, 4:1388-1398.
46. Yip E.C., Chan A.S., Pang H., Tam Y.K., Wong Y.H. Protocatechuic acid induces cell death in HepG2 hepatocellular carcinoma cells through a c-Jun N-terminal kinase-dependent mechanism. Cell Biol. Toxicol. 2006, 22:293-302.
47. Yu J., Zhang L. The transcriptional targets of p53 in apoptosis control. Biochem. Biophys. Res. Commun. 2005, 331:851-858.
48. Zhang S., Won Y.K., Ong C.N., Shen H.M. Anti-cancer potential of sesquiterpene lactones: bioactivity and molecular mechanisms. Curr. Med. Chem. Anticancer Agents 2005, 5:239-249.
49. Zhou M., Gu L., Zhu N., Woods W.G., Findley H.W. Transfection of a dominant- negative mutant NF- kB inhibitor (IkBm) represses p53-dependent apoptosis in acute lymphoblastic leukemia cells: interaction of IkBm and p53. Oncogene 2003, 22:8137-8144.